Foscarnet

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 466101

CAS#: 4428-95-9 (free acid)

Description: Foscarnet is a structural mimic of the anion pyrophosphate that selectively inhibits the pyrophosphate binding site on viral DNA polymerases at concentrations that do not affect human DNA polymerases. In individuals treated with the DNA polymerase inhibitors acyclovir or ganciclovir, HSV or CMV particles can develop mutant protein kinases (thymidine kinase or UL97 protein kinase, respectively) that make them resistant to these antiviral drugs. However, unlike acyclovir and ganciclovir, foscarnet is not activated by viral protein kinases, making it useful in acyclovir- or ganciclovir-resistant HSV and CMV infections.

Chemical Structure

img
Foscarnet
CAS# 4428-95-9 (free acid)
Instruction

Theoretical Analysis

MedKoo Cat#: 466101
Name: Foscarnet
CAS#: 4428-95-9 (free acid)
Chemical Formula: CH3O5P
Exact Mass: 125.97
Molecular Weight: 126.004
Elemental Analysis: C, 9.53; H, 2.40; O, 63.49; P, 24.58

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 63585-09-1 (sodium)   4428-95-9 (free acid)    

Synonym: Carboxyphosphonic acid; Foscarnet; PFA; Phosphonic acid, carboxy-; Phosphonocarboxylic acid; Phosphonoformic acid;

IUPAC/Chemical Name: phosphonoformic acid

InChi Key: ZJAOAACCNHFJAH-UHFFFAOYSA-N

InChi Code: InChI=1S/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6)

SMILES Code: OC(P(O)(O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 126.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Irie K, Hiramoto N, Yamaoka K, Fuckushima S. Cerebrospinal fluid concentration of foscarnet in patients with HHV-6 encephalitis after haematopoietic stem cell transplantation. J Antimicrob Chemother. 2023 Apr 18:dkad117. doi: 10.1093/jac/dkad117. Epub ahead of print. PMID: 37071595.


2: Vittayawacharin P, E'Leimat G, Lee BJ, Griffin S, Doh J, Nam H, Blodget E, Jeyakumar D, Kongtim P, Ciurea SO. Once-Daily Foscarnet Is Effective for Human Herpesvirus 6 Reactivation after Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023 Mar 4:S2666-6367(23)01132-6. doi: 10.1016/j.jtct.2023.02.022. Epub ahead of print. PMID: 36878429.


3: Ma R, He Y, Xu LP, Zhang XH, Wang Y, Liu KY, Huang XJ, Sun YQ. [Clinical analysis of the efficacies of ganciclovir plus foscarnet and a single antiviral drug for the treatment of cytomegalovirus infection after haploidentical stem cell transplantation]. Zhonghua Nei Ke Za Zhi. 2023 Jan 1;62(1):76-83. Chinese. doi: 10.3760/cma.j.cn112138-20220118-00058. PMID: 36631041.


4: Garikapati S, Nguyen M. Foscarnet. 2023 Jan 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 32310568.


5: Lee HJ, Woo SJ. Efficacy of ganciclovir versus foscarnet in ganciclovir- resistant cytomegalovirus retinitis: A case report. Eur J Ophthalmol. 2022 Oct 30:11206721221136316. doi: 10.1177/11206721221136316. Epub ahead of print. PMID: 36314436.


6: Cho J, Bhavsar AR, Cho DH, Sattarova V, Abel AS, Zadroga R. Successful Treatment of Epstein-Barr Virus-Induced Necrotizing Retinitis with Intravitreous Ganciclovir, Foscarnet, and Methotrexate. Case Rep Ophthalmol. 2022 Mar 4;13(1):116-123. doi: 10.1159/000520408. PMID: 35431884; PMCID: PMC8958626.


7: Khorenko M, Rand U, Cicin-Sain L, Feldmann C. Foscarnet-Type Inorganic- Organic Hybrid Nanoparticles for Effective Antiviral Therapy. ACS Biomater Sci Eng. 2022 Apr 11;8(4):1596-1603. doi: 10.1021/acsbiomaterials.2c00074. Epub 2022 Mar 28. PMID: 35344659; PMCID: PMC9007112.


8: Suzuki K, Namba K, Hase K, Mizuuchi K, Iwata D, Ito T, Kitaichi N, Takase H, Ishida S. A case of Epstein-Barr virus acute retinal necrosis successfully treated with foscarnet. Am J Ophthalmol Case Rep. 2022 Jan 29;25:101363. doi: 10.1016/j.ajoc.2022.101363. PMID: 35146210; PMCID: PMC8818534.


9: Inose R, Takahashi K, Takahashi M, Sugimoto T, Nanno S, Hino M, Nagayama K. Long-term use of foscarnet is associated with an increased incidence of acute kidney injury in hematopoietic stem cell transplant patients: A retrospective observational study. Transpl Infect Dis. 2022 Apr;24(2):e13804. doi: 10.1111/tid.13804. Epub 2022 Feb 10. PMID: 35114030.


10: Hermoso-Fernández FM, Gonzalez-Gallardo C, Cruz-Rojo M. Acute retinal necrosis: time to consider double dose of Foscarnet in the first 72 hours. Rom J Ophthalmol. 2021 Jul-Sep;65(3):267-270. doi: 10.22336/rjo.2021.53. PMID: 35036649; PMCID: PMC8697778.


11: Irie K, Hiramoto N, Ishikawa T, Fukushima S. Use of liquid chromatography- tandem mass spectrometry for foscarnet quantification in human serum and cerebrospinal fluid. Rapid Commun Mass Spectrom. 2022 Apr 15;36(7):e9255. doi: 10.1002/rcm.9255. PMID: 35001441.


12: Pleško J, Kovač D, Arsov Z, Lindič J, Škoberne A, Ferluga D, Kojc N. Glomerular and tubulointerstitial foscarnet nephropathy of kidney allograft with emphasis on ultrastructural findings: A case report. Clin Nephrol. 2021 Suppl;96(1):127-132. doi: 10.5414/CNP96S23. PMID: 34643504.


13: Yu Y, Bao R, Lyu J, Wu J, Chen J, Peng W. Foscarnet Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection in Kidney Transplant Recipients: A Preliminary Exploration. Infect Drug Resist. 2021 Jul 27;14:2911-2923. doi: 10.2147/IDR.S321936. PMID: 34349526; PMCID: PMC8326942.


14: Rho E, Näf B, Müller TF, Wüthrich RP, Schachter T, von Moos S. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients. Clin Transplant. 2021 Nov;35(11):e14401. doi: 10.1111/ctr.14401. Epub 2021 Oct 28. PMID: 34181768; PMCID: PMC9285377.


15: Ota R, Hirata A. Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet. J Chemother. 2021 Dec;33(8):539-546. doi: 10.1080/1120009X.2021.1915074. Epub 2021 Jun 1. PMID: 34060436.


16: Domingo W, Nguyen IT, Johnsrud JJ, Brown JW. Continuous-Infusion Foscarnet Facilitates Administration in Hematopoietic Stem Cell Transplantation Patients. Transplant Cell Ther. 2021 Jul;27(7):622.e1-622.e5. doi: 10.1016/j.jtct.2021.03.018. Epub 2021 Mar 23. PMID: 33891883.


17: Zarrouk K, Zhu X, Pham VD, Goyette N, Piret J, Shi R, Boivin G. Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0039021. doi: 10.1128/AAC.00390-21. Epub 2021 Jun 17. PMID: 33875432; PMCID: PMC8218610.


18: Miyao K, Terakura S, Ozawa Y, Sawa M, Kohno A, Kasahara S, Iida H, Ino K, Kusumoto S, Kasai M, Takami A, Kurahashi S, Kajiguchi T, Morishita T, Nishida T, Murata M; Nagoya Blood and Marrow Transplantation Group. Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy. Transplant Cell Ther. 2021 Apr;27(4):342.e1-342.e10. doi: 10.1016/j.jtct.2020.12.012. Epub 2020 Dec 16. PMID: 33836887.


19: Vassallo F, Nuzzi R, Cattani I, Dellacasa C, Giaccone L, De Rosa FG, Cavallo R, Iovino G, Brunello L, Bruno B, Busca A. CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins. Ther Adv Hematol. 2020 Dec 10;11:2040620720975651. doi: 10.1177/2040620720975651. PMID: 33354311; PMCID: PMC7734499.


20: Deffert C, Stoermann C, Ernandez T, Nabergoj M, Chalandon Y, Jaeger P. Phosphonoformate Crystalluria, A Warning Signal of Foscarnet-Induced Kidney Injury. Kidney Int Rep. 2020 Aug 22;5(11):2102-2108. doi: 10.1016/j.ekir.2020.08.019. PMID: 33163731; PMCID: PMC7609899.